{"entity":{"id":"dositinib","kind":"drug","name":"Dositinib","aka":["90-1408","哆希替尼"],"tldr":"Dositinib is an experimental small molecule from Henan Genuine Biotech, in phase 2 trials for EGFR-mutant non-small cell lung cancer.","summary":"Dositinib (90-1408, 哆希替尼) is a small molecule (oral EGFR tyrosine kinase inhibitor) from Henan Genuine Biotech. An EGFR tyrosine kinase inhibitor taken as a tablet. Its furthest stage is phase 2, for EGFR-mutant non-small cell lung cancer. ClinicalTrials.gov registers it in 2 studies linked below. Phase 1/2 NCT07231068 in EGFR-mutant NSCLC recruiting (started October 2022); also in NCT07362940 with GEN-725. Whether it works in people has not been established unless a trial below reports it.","status":"phase-2","asOf":"2026-11-03","links":[{"label":"Henan Genuine Biotech: clinicaltrials.gov","url":"https://clinicaltrials.gov/study/NCT07231068"},{"label":"Henan Genuine Biotech: genuine-bio.com","url":"https://genuine-bio.com/research.html"},{"label":"ClinicalTrials.gov: trials of Dositinib","url":"https://clinicaltrials.gov/search?intr=Dositinib"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":["henan-genuine-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07231068","nct07362940"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"Dositinib","modality":"Small molecule (oral EGFR tyrosine kinase inhibitor)","mechanism":"An EGFR tyrosine kinase inhibitor taken as a tablet.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/dositinib/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"}],"company":[{"id":"henan-genuine-biotech","kind":"company","name":"Henan Genuine Biotech","route":"/companies/henan-genuine-biotech/"}],"trial":[{"id":"nct07231068","kind":"trial","name":"A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation","route":"/trials/nct07231068/"},{"id":"nct07362940","kind":"trial","name":"A Phase Ⅰ/Ⅱa Clinical Study of GEN-725 in Combination With Dositinib","route":"/trials/nct07362940/"}]}}